Development of arabinoxylan-reinforced apple pectin/graphene oxide/nano-hydroxyapatite based nanocomposite scaffolds with controlled release of drug for bone tissue engineering: In-vitro evaluation of biocompatibility and cytotoxicity against MC3T3-E1

Abstract

Fabrication of reinforced scaffolds to repair and regenerate defected bone is still a major challenge. Bone tissue engineering is an advanced medical strategy to restore or regenerate damaged bone. The excellent biocompatibility and osteogenesis behavior of porous scaffolds play a critical role in bone regeneration. In current studies, we synthesized polymeric nanocomposite material through free-radical polymerization to fabricate porous nanocomposite scaffolds by freeze drying. Functional group, surface morphology, porosity, pore size, and mechanical strength were examined through Fourier Transform Infrared Spectroscopy (FTIR), Single-Electron Microscopy (SEM), Brunauer-Emmet-Teller (BET), and Universal Testing Machine (UTM), respectively. These nanocomposites exhibit enhanced compressive strength (from 4.1 to 16.90 MPa), Young’s modulus (from 13.27 to 29.65 MPa) with well appropriate porosity and pore size (from 63.72 ± 1.9 to 45.75 ± 6.7 µm), and a foam-like morphology. The increasing amount of graphene oxide (GO) regulates the porosity and mechanical behavior of the nanocomposite scaffolds. The loading and sustained release of silver-sulfadiazine was observed to be 90.6% after 260 min. The in-vitro analysis was performed using mouse pre-osteoblast (MC3T3-E1) cell lines. The developed nanocomposite scaffolds exhibited excellent biocompatibility. Based on the results, we propose these novel nanocomposites can serve as potential future biomaterials to repair defected bone with the load-bearing application, and in bone tissue engineering.